Activity Profile of an FDA-Approved Compound Library against Schistosoma mansoni.

ABSTRACT:

Background

As plans to expand mass drug treatment campaigns to fight schistosomiasis form, worries about reliance on praziquantel as the sole available treatment motivate the investigation for novel antischistosomal compounds. Drug repurposing might be an inexpensive and effective source of novel antischistosomal leads.

Methodology

1600 FDA approved compounds were first assayed against Schistosoma mansoni schistosomula at a concentration of 10 µM. Active compounds identified from this screen were advanced to the adult worm screen at 33.33 µM, followed by hit characterization. Leads with complementary pharmacokinetic and toxicity profiles were then selected for in vivo studies.

Principal findings

The in vitro screen identified 121 and 36 compounds active against the sc

SUBMITTER: Panic G 

PROVIDER: S-EPMC4521867 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature